Pharmacological experiments in mice with gastric cancer showed that TPS could increase the serum levels of interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10), Immunoglobulin M (IgM), Immunoglobulin M (IgG), and Immunoglobulin A (IgA) in mice and reduce the level of MDA in gastric tissue and the levels of interleukin-6 (IL-6) and TNF-α in serum, which suggests that TPS might be a potential modulator in the intervention of gastric cancer [132]. This evidence concerns the gene CD40LG and gastric cancer.